Abstract
Correctional facilities provide unique opportunities to diagnose and treat persons with latent tuberculosis infection (LTBI). Studies have shown that 12 weekly doses of isoniazid and rifapentine (INH-RPT) to treat LTBI resulted in high completion rates with good tolerability. To evaluate completion rates and clinical signs or reported symptoms associated with discontinuation of 12 weekly doses of INH-RPT for LTBI treatment. During July 2012 to February 2015, 7 Federal Bureau of Prisons facilities participated in an assessment of 12 weekly doses of INH-RPT for LTBI treatment among 463 inmates. Fisher exact test was used to assess the associations between patient sociodemographic characteristics and clinical signs or symptoms with discontinuation of treatment. Of 463 inmates treated with INH-RPT, 424 (92%) completed treatment. Reasons for discontinuation of treatment for 39 (8%) inmates included the following: 17 (44%) signs/symptoms, 9 (23%) transfer or release, 8 (21%) treatment refusal, and 5 (13%) provider error. A total of 229 (49.5%) inmates reported experiencing at least 1 sign or symptom during treatment; most frequently reported were fatigue (16%), nausea (13%), and abdominal pain (7%). Among these 229 inmates, signs/sym...Continue Reading
References
Dec 13, 1993·Archives of Internal Medicine·A R PelletierC L Woodley
Feb 1, 1997·American Journal of Respiratory and Critical Care Medicine·F ChavesJ H Bates
Feb 1, 1997·American Journal of Public Health·D T KooG W Rutherford
Jun 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C R MacIntyreN M Graham
Mar 10, 1998·American Journal of Public Health·J P TulskyG Schecter
Mar 27, 2003·American Journal of Preventive Medicine·Mark N LobatoPatricia M Simone
Oct 26, 2005·American Journal of Preventive Medicine·Mary C WhiteL Masae Kawamura
Jan 5, 2011·PLoS Medicine·Iacopo BaussanoFabio Scano
Dec 14, 2011·The New England Journal of Medicine·Timothy R SterlingUNKNOWN TB Trials Consortium PREVENT TB Study Team
Mar 14, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·H A A Al-DarrajiF L Altice
Aug 12, 2015·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·E E Bliven-SizemoreUNKNOWN TB Trials Consortium
Nov 5, 2015·PloS One·Roque MiramontesPhilip A LoBue
Feb 13, 2016·American Journal of Respiratory and Critical Care Medicine·James D MancusoTzu-Cheg Kao
Feb 18, 2016·Open Forum Infectious Diseases·Maria Juarez-ReyesNeha S Shah
Sep 16, 2016·American Journal of Public Health·Lauren A LambertMaryam B Haddad
Citations
Sep 12, 2019·Journal of Forensic Sciences·Brett O GardnerKaren D H Pan
Feb 7, 2020·Journal of Neurotrauma·Amery Treble-BarnaBrad G Kurowski
May 8, 2020·International Journal of Circumpolar Health·G G AlvarezA Zwerling
Nov 16, 2019·The Annals of Pharmacotherapy·Ramara E WalkerAndrea M Pallotta
Mar 27, 2021·The Lancet Child & Adolescent Health·Amyn A MalikHamidah Hussain